A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business. We are a medical device company focusing on the development and commercialization of products for the treatment of carotid artery disease and other vascular disease, including our proprietary CGuard™ stent platform. A stent is an expandable scaffold-like device, usually constructed of a metallic material, that is inserted into the lumen of an artery to create patency and improved blood flow. A sleeve of MicroNet™ mesh is attached over a stent to provide embolic protection both during and after stenting procedures. Our CGuard™ carotid embolic prevention system (“CGuard EPS”) combines MicroNet and a unique self-expandable nitinol stent in a single device for use in carotid artery revascularization. Our CGuard EPS originally received CE mark approval under Medical Device Directive 93/42/EEC (“MDD”) in the European Union (“EU”) in March 2013 and was fully launched in Europe in September 2015.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 7.8M | - | - | - | - | - |
| Net Income | -46M | -32M | -20M | -18M | -15M | -11M |
| EPS | $-0.82 | $-0.76 | $-0.82 | $-2.35 | $-2.03 | $-6.97 |
| Free Cash Flow | -34M | -23M | -17M | -16M | -14M | -9.2M |
| ROIC | -47.2% | -88.7% | -50.4% | -85.0% | -44.5% | -86.7% |
| Gross Margin | 24.9% | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.30 | 0.21 | 0.42 | 0.18 | 0.46 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -47M | -34M | -21M | -19M | -15M | -10M |
| Operating Margin | -602.9% | - | - | - | - | - |
| ROE | -72.1% | -84.7% | -50.4% | -106.3% | -44.5% | -86.7% |
| Shares Outstanding | 42M | 42M | 24M | 23M | 7M | 8M |
InspireMD, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
InspireMD, Inc. (NSPR) has a 5-year average return on invested capital (ROIC) of -71.1%. This is below average and may indicate limited pricing power.
InspireMD, Inc. (NSPR) has a market capitalization of $57M. It is classified as a small-cap stock.
InspireMD, Inc. (NSPR) does not currently pay a regular dividend.
InspireMD, Inc. (NSPR) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
InspireMD, Inc. (NSPR) generated $-23 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
InspireMD, Inc. (NSPR) has a debt-to-equity ratio of 0.30. This indicates a conservatively financed balance sheet.
InspireMD, Inc. (NSPR) reported earnings per share (EPS) of $-0.76 in its most recent fiscal year.
InspireMD, Inc. (NSPR) has a return on equity (ROE) of -84.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for InspireMD, Inc. (NSPR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
InspireMD, Inc. (NSPR) has a book value per share of $0.86, based on its most recent annual SEC filing.